Global Alzheimer’s Platform (GAP) Foundation is promoting innovative and easier?to?use clinical trial participation tools, including the Brain Health Registry
WASHINGTON, D.C. (July 18, 2016) – In a first?ever poll conducted online by Harris Poll on behalf of the Global Alzheimer’s Platform (GAP) Foundation, nearly 60% of Americans report they are definitely willing or would consider participating in Alzheimer’s disease clinical trials, but participation rates show that less than 10% are actually doing so (source). The failure to provide willing Americans more information and easier?to?use tools for participation could be seen as weakening the attack on America’s most feared disease (source).
At this very moment, 17 Alzheimer’s disease treatments are in Phase 3 clinical trials and on pace to get to market in the next five years, if successful in their trials and approved by the FDA (source). Any successful drug would be the first new therapy on the market in over a decade. To make this five?year aggressive timeline a reality, clinical trial participants are needed now. Recent data collected by the GAP Foundation finds that Americans are ready and willing to help, but lack of participation suggests they do not have the information and tools to do so.
Obtaining qualified trial participants has been one of the greatest challenges in getting clinical trials off the ground, which is why the GAP Foundation commissioned a survey to examine Americans’ perceptions about Alzheimer’s disease and to gauge their willingness to participate in clinical trials.
“We’re closer than ever to finding a treatment for Alzheimer’s, but we need an engaged army of citizen scientists to push these drugs over the line,” said George Vradenburg, co?founder of GAP Foundation and USAgainstAlzheimer’s. “Clinical trials are the ticket to making a cure happen. The first person cured of Alzheimer’s will be in an Alzheimer’s clinical trial.”
John Dwyer, president of the GAP Foundation, added, “One of the reasons we founded the Global Alzheimer’s Platform Foundation was because we heard from dozens of research institutions across the country that they were having difficulty finding and enrolling trial?ready candidates. GAP Foundation’s role in this ongoing effort has been to build better tools and greater awareness of Alzheimer’s clinical trials to accelerate clinical trials.”
The GAP Foundation’s national survey of 2,056 Americans ages 18 and older revealed two clear themes:
1. A majority (59%) of Americans are definitely willing or willing to consider taking part in an Alzheimer’s clinical trial.
- 20% of Americans said they would definitely be willing to take part in a clinical trial. 22% of Millennials ages 18?34 said they would definitely be willing and 13% of adults ages 65+ said they would definitely be willing.
- 39% of Americans said they would be willing to consider taking part in an Alzheimer’s clinical trial.Dwyer continues, “Data shows us that the willingness to participate in clinical trials is there, so our next step is to bridge the gap between willingness and actual participation. The way we do that, is to make it as simple as possible for people to learn about what clinical trials they qualify for and how to sign up.”
2. Among those surveyed, willingness to participate in Alzheimer’s clinical trials remains relatively strong among African American, Hispanics* and Whites. In reality, far less a percentage of African Americans and Hispanics are enrolled in clinical trials, making minority recruitment into clinical trials a high priority (source).
- 20% of Americans are definitely willing to take part in a clinical trial, including 24% who are African American, 16% who are Hispanic and 20% who are White.
- 39% of Americans said they would consider taking part in an Alzheimer’s clinical trial, including 34% who are African American, 41% who are Hispanic and 39% who are White.
“African Americans are two to three times more likely to experience Alzheimer’s than Whites, and Hispanics are one and a half times as likely to experience Alzheimer’s as non?Hispanic whites, making their greater representation in clinical trials a matter of the highest priority,” said Vradenburg.
The Global Alzheimer’s Platform Foundation urges the following actions to help in the fight against Alzheimer’s disease:
- Register free at www.brainhealthregistry.org. The Brain Health Registry (BHR) is a free, online platform designed to speed the path to cures for Alzheimer’s disease and other brain disorders. BHR gathers data from volunteers who have registered and completed questionnaires and cognitive tests via its website. BHR aims to reduce the cost of patient recruitment for clinical trials by building a large online pool of potential, trial?ready candidates.
- Recognize the beginning signs and symptoms of Alzheimer’s disease, such as:
- Memory loss
- Difficulty planning and solving problems o Difficulty completing familiar tasks
- Difficulty determining time or place
- Difficulty finding the right words
- Misplacing items often
3. If you are experiencing memory loss that disrupts your daily life, please seek the help of a medical professional right away.
Additional Findings:
- 25% of Americans have/had a family member with the disease.
- 17% of Millennials ages 18?34 believe, incorrectly, that there is a cure for Alzheimer’s disease today.
- More than 3 in 5 Americans (62%) believe Hillary Clinton will do more than Donald Trump (38%) to help in the fight against Alzheimer’s disease.
- 73% of Americans who do not have Alzheimer’s disease say that if they were to develop the disease, their biggest fear would be not knowing how their family would pay for their care.
- 28% of Americans believe that health insurance usually covers most of the cost of care for someone with Alzheimer’s disease.
- 23% of Americans most feared developing Alzheimer’s disease, more than the 18% who said they most feared having a heart attack and 7% who most feared getting shot. 27% most feared another major economic crisis, while 26% said they most feared being targeted in a terrorist attack.
Read the full release here.